BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$91.20 USD
-0.86 (-0.93%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $91.23 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
BMRN 91.20 -0.86(-0.93%)
Will BMRN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMRN
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics
Other News for BMRN
BioMarin: Q1 Earnings Snapshot
BioMarin Reports Record Financial Results for the First Quarter 2024
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript
BioMarin Pharmaceutical Inc. 2024 Q1 - Results - Earnings Call Presentation